Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD) (QUANTIFY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01574651
Recruitment Status : Completed
First Posted : April 10, 2012
Results First Posted : April 29, 2014
Last Update Posted : May 22, 2014
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Study Type Interventional
Study Design Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double (Participant, Investigator);   Primary Purpose: Treatment
Condition Chronic Obstructive Pulmonary Disease (COPD)
Interventions Drug: QVA149
Drug: Placebo to tiotropium
Drug: Placebo to formoterol
Drug: Tiotropium
Drug: Formoterol
Drug: Placebo to QVA149
Enrollment 934
Recruitment Details  
Pre-assignment Details  
Arm/Group Title QVA149 Plus Placebo to Tiotropium and Placebo to Formoterol Tiotropium Plus Formoterol and Placebo to QVA149
Hide Arm/Group Description QVA149 110/50µg, once daily for inhalation use plus placebo to tiotropium, once daily for inhalation use and placebo to formoterol, twice daily for inhalation use. Tiotropium 18µg, once daily for inhalation use plus Formoterol 12µg, twice daily for inhalation use and placebo to QVA149, once daily for inhalation use.
Period Title: Overall Study
Started 476 458
Full Analysis Set (FAS) 476 458
Per Protocol Set (PPS) 373 374
Completed 415 406
Not Completed 61 52
Reason Not Completed
Lost to Follow-up             2             4
Administrative problems             0             1
Death             3             3
Patient's inability to use the device             0             1
Adverse Event             36             27
Abnormal laboratory value(s)             1             0
Abnormal test procedure result(s)             1             1
Unsatisfactory therapeutic effect             6             0
Protocol Violation             3             5
Withdrawal by Subject             9             10
Arm/Group Title QVA149 Plus Placebo to Tiotropium and Placebo to Formoterol Tiotropium Plus Formoterol and Placebo to QVA149 Total
Hide Arm/Group Description QVA149 110/50µg, once daily for inhalation use plus placebo to tiotropium, once daily for inhalation use and placebo to formoterol, twice daily for inhalation use. Tiotropium 18µg, once daily for inhalation use plus Formoterol 12µg, twice daily for inhalation use and placebo to QVA149, once daily for inhalation use. Total of all reporting groups
Overall Number of Baseline Participants 476 458 934
Hide Baseline Analysis Population Description
[Not Specified]
Age, Continuous  
Mean (Standard Deviation)
Unit of measure:  Years
Number Analyzed 476 participants 458 participants 934 participants
62.6  (8.43) 63.1  (8.15) 62.9  (8.29)
Sex: Female, Male  
Measure Type: Count of Participants
Unit of measure:  Participants
Number Analyzed 476 participants 458 participants 934 participants
Female
159
  33.4%
160
  34.9%
319
  34.2%
Male
317
  66.6%
298
  65.1%
615
  65.8%
1.Primary Outcome
Title St. George's Respiratory Questionnaire (SGRQ-C) Total Score After 26 Weeks of Treatment (Non-inferiority Analysis).
Hide Description SGRQ is a health related quality of life questionnaire consisting of 40 items in three areas: symptoms (respiratory symptoms and severity), activity (activities that cause or are limited by breathlessness) and impacts (social functioning and psychological disturbances due to airway disease). The total score is 0 to 100 with a higher score indicating poorer health status. For patients who completed the study but with missing SGRQ-C during treatment, the missing SGRQ-C were replaced by the last observation carried forward (LOCF). Symptom scores were expected to improve over treatment, therefore the replacement of missing values with earlier measurements did not result in overoptimistic imputation and this procedure could be regarded as conservative.
Time Frame Baseline, week 26
Hide Outcome Measure Data
Hide Analysis Population Description
Full analysis set (FAS): all randomized patients who received at least one dose of randomized study drug. Following the ITT principle, patients were analyzed according to the treatment they were assigned to. The FAS was used for all efficacy variables unless otherwise stated.
Arm/Group Title QVA149 Plus Placebo to Tiotropium and Placebo to Formoterol Tiotropium Plus Formoterol and Placebo to QVA149
Hide Arm/Group Description:
QVA149 110/50µg, once daily for inhalation use plus placebo to tiotropium, once daily for inhalation use and placebo to formoterol, twice daily for inhalation use.
Tiotropium 18µg, once daily for inhalation use plus Formoterol 12µg, twice daily for inhalation use and placebo to QVA149, once daily for inhalation use.
Overall Number of Participants Analyzed 476 458
Mean (Standard Deviation)
Unit of Measure: Score on a scale
Baseline (n=452,441) 44.70  (17.718) 45.68  (17.720)
Week 26 (n=475,456) 41.30  (19.923) 43.19  (19.284)
2.Secondary Outcome
Title St. George's Respiratory Questionnaire (SGRQ-C) Total Score After 26 Weeks of Treatment (Superiority Analysis).
Hide Description SGRQ is a health related quality of life questionnaire consisting of 40 items in three areas: symptoms (respiratory symptoms and severity), activity (activities that cause or are limited by breathlessness) and impacts (social functioning and psychological disturbances due to airway disease). The total score is 0 to 100 with a higher score indicating poorer health status. For patients who completed the study but with missing SGRQ-C during treatment, the missing SGRQ-C were replaced by the last observation carried forward (LOCF). Symptom scores were expected to improve over treatment, therefore the replacement of missing values with earlier measurements did not result in overoptimistic imputation and this procedure could be regarded as conservative. Superiority of QVA 110/50 μg to tiotropium 18 μg q.d. plus formoterol 12 μg b.i.d. in terms of health related quality of life as assessed by St George's Respiratory Questionnaire (SGRQ-C) after 26 weeks of treatment
Time Frame Baseline, week 26
Hide Outcome Measure Data
Hide Analysis Population Description
Full analysis set (FAS): all randomized patients who received at least one dose of randomized study drug. Following the ITT principle, patients were analyzed according to the treatment they were assigned to. The FAS was used for all efficacy variables unless otherwise stated
Arm/Group Title QVA149 Plus Placebo to Tiotropium and Placebo to Formoterol Tiotropium Plus Formoterol and Placebo to QVA149
Hide Arm/Group Description:
QVA149 110/50µg, once daily for inhalation use plus placebo to tiotropium, once daily for inhalation use and placebo to formoterol, twice daily for inhalation use.
Tiotropium 18µg, once daily for inhalation use plus Formoterol 12µg, twice daily for inhalation use and placebo to QVA149, once daily for inhalation use.
Overall Number of Participants Analyzed 476 458
Mean (Standard Deviation)
Unit of Measure: Score on a scale
Baseline (n=452,441) 44.70  (17.718) 45.68  (17.720)
Week 26 (n=475,456) 41.30  (19.923) 43.19  (19.284)
3.Secondary Outcome
Title Transition Dyspnea Index (TDI) Focal Score After 26 Weeks of Treatment.
Hide Description Baseline Dyspnea Index (BDI)/Transition Dyspnea Index (TDI) focal score is based on three domains: functional impairment, magnitude of task and magnitude of effort and captures changes from baseline. BDI was measured at day 1 prior to the first dose with domain scores ranging from 0=very severe to 4=no impairment and a total score ranging from 0 to 12(best). TDI captures changes from baseline. Each domain is scored from -3=major deterioration to 3=major improvement to give an overall TDI focal score of -9 to 9. Higher numbers indicate a better score. missing values were replaced by the latest observed value (LOCF)
Time Frame Week 26
Hide Outcome Measure Data
Hide Analysis Population Description
Full analysis set (FAS): all randomized patients who received at least one dose of randomized study drug. Following the ITT principle, patients were analyzed according to the treatment they were assigned to. The FAS was used for all efficacy variables unless otherwise stated
Arm/Group Title QVA149 Plus Placebo to Tiotropium and Placebo to Formoterol Tiotropium Plus Formoterol and Placebo to QVA149
Hide Arm/Group Description:
QVA149 110/50µg, once daily for inhalation use plus placebo to tiotropium, once daily for inhalation use and placebo to formoterol, twice daily for inhalation use.
Tiotropium 18µg, once daily for inhalation use plus Formoterol 12µg, twice daily for inhalation use and placebo to QVA149, once daily for inhalation use.
Overall Number of Participants Analyzed 462 443
Mean (Standard Deviation)
Unit of Measure: Units on a scale
1.34  (3.440) 0.87  (3.439)
4.Secondary Outcome
Title Percent of Participants With at Least One Exacerbation Requiring Systemic Corticosteroids and/or Antibiotics Over 26 Weeks
Hide Description The percent of participants with at least one moderate exacerbation within the 26 weeks that required systemic corticosteroids and/or antibiotics during the treatment
Time Frame Week 26
Hide Outcome Measure Data
Hide Analysis Population Description
Full analysis set (FAS): all randomized patients who received at least one dose of randomized study drug. Following the ITT principle, patients were analyzed according to the treatment they were assigned to. The FAS was used for all efficacy variables unless otherwise stated
Arm/Group Title QVA149 Plus Placebo to Tiotropium and Placebo to Formoterol Tiotropium Plus Formoterol and Placebo to QVA149
Hide Arm/Group Description:
QVA149 110/50µg, once daily for inhalation use plus placebo to tiotropium, once daily for inhalation use and placebo to formoterol, twice daily for inhalation use.
Tiotropium 18µg, once daily for inhalation use plus Formoterol 12µg, twice daily for inhalation use and placebo to QVA149, once daily for inhalation use.
Overall Number of Participants Analyzed 476 458
Measure Type: Number
Unit of Measure: Percent of participants
10.9 13.3
5.Secondary Outcome
Title Percent of Participants With at Least One Exacerbation Requiring Hospitalization
Hide Description The percent of patients with at least one severe exacerbation within the 26 weeks that required hospitalization. COPD exacerbations were considered to be severe if hospitalization were required.
Time Frame Week 26
Hide Outcome Measure Data
Hide Analysis Population Description
Full analysis set (FAS): all randomized patients who received at least one dose of randomized study drug. Following the ITT principle, patients were analyzed according to the treatment they were assigned to. The FAS was used for all efficacy variables unless otherwise stated
Arm/Group Title QVA149 Plus Placebo to Tiotropium and Placebo to Formoterol Tiotropium Plus Formoterol and Placebo to QVA149
Hide Arm/Group Description:
QVA149 110/50µg, once daily for inhalation use plus placebo to tiotropium, once daily for inhalation use and placebo to formoterol, twice daily for inhalation use.
Tiotropium 18µg, once daily for inhalation use plus Formoterol 12µg, twice daily for inhalation use and placebo to QVA149, once daily for inhalation use.
Overall Number of Participants Analyzed 476 458
Measure Type: Number
Unit of Measure: Percent of participants
2.1 2.4
6.Secondary Outcome
Title Time- Event Analysis, Number of Participants With at Least One COPD Exacerbation (Moderate or Severe) During the Treatment Period
Hide Description The number of participants with at least one moderate or severe COPD exacerbation. COPD exacerbations are considered to be moderate if treatment with systemic corticosteroids and/or antibiotics was required. COPD exacerbations are considered to be severe if hospitalizations were required.
Time Frame Week 26
Hide Outcome Measure Data
Hide Analysis Population Description
Full analysis set (FAS): all randomized patients who received at least one dose of randomized study drug. Following the ITT principle, patients were analyzed according to the treatment they were assigned to. The FAS was used for all efficacy variables unless otherwise stated
Arm/Group Title QVA149 Plus Placebo to Tiotropium and Placebo to Formoterol Tiotropium Plus Formoterol and Placebo to QVA149
Hide Arm/Group Description:
QVA149 110/50µg, once daily for inhalation use plus placebo to tiotropium, once daily for inhalation use and placebo to formoterol, twice daily for inhalation use.
Tiotropium 18µg, once daily for inhalation use plus Formoterol 12µg, twice daily for inhalation use and placebo to QVA149, once daily for inhalation use.
Overall Number of Participants Analyzed 476 458
Measure Type: Number
Unit of Measure: Participants
62 70
7.Secondary Outcome
Title Trough FEV1 at Baseline and Week 26
Hide Description Trough FEV1 is the mean value of FEV1 (forced expiratory volume in one second) measured at 23:15h and 23:45h after the morning doses. The baseline value was measured at day 1 prior to the first dose.
Time Frame Baseline, Week 26
Hide Outcome Measure Data
Hide Analysis Population Description
Full analysis set (FAS): all randomized patients who received at least one dose of randomized study drug. Following the ITT principle, patients were analyzed according to the treatment they were assigned to. The FAS was used for all efficacy variables unless otherwise stated
Arm/Group Title QVA149 Plus Placebo to Tiotropium and Placebo to Formoterol Tiotropium Plus Formoterol and Placebo to QVA149
Hide Arm/Group Description:
QVA149 110/50µg, once daily for inhalation use plus placebo to tiotropium, once daily for inhalation use and placebo to formoterol, twice daily for inhalation use.
Tiotropium 18µg, once daily for inhalation use plus Formoterol 12µg, twice daily for inhalation use and placebo to QVA149, once daily for inhalation use.
Overall Number of Participants Analyzed 476 458
Mean (Standard Deviation)
Unit of Measure: Liters
Baseline 1.329  (0.4806) 1.313  (0.4525)
Week 26 1.495  (0.5060) 1.409  (0.4878)
8.Secondary Outcome
Title FEV1 30 Min After the Morning Dose at Baseline and Week 26
Hide Description FEV1 30min is the forced expiratory volume in one second measured 30 min after the morning dose.
Time Frame Baseline, Week 26
Hide Outcome Measure Data
Hide Analysis Population Description
Full analysis set (FAS): all randomized patients who received at least one dose of randomized study drug. Following the ITT principle, patients were analyzed according to the treatment they were assigned to. The FAS was used for all efficacy variables unless otherwise stated
Arm/Group Title QVA149 Plus Placebo to Tiotropium and Placebo to Formoterol Tiotropium Plus Formoterol and Placebo to QVA149
Hide Arm/Group Description:
QVA149 110/50µg, once daily for inhalation use plus placebo to tiotropium, once daily for inhalation use and placebo to formoterol, twice daily for inhalation use.
Tiotropium 18µg, once daily for inhalation use plus Formoterol 12µg, twice daily for inhalation use and placebo to QVA149, once daily for inhalation use.
Overall Number of Participants Analyzed 476 458
Mean (Standard Deviation)
Unit of Measure: Liters
Baseline (n=475,458) 1.517  (0.5025) 1.495  (0.4860)
Week 26 (n=476,458) 1.605  (0.5356) 1.565  (0.5124)
9.Secondary Outcome
Title Symptoms Score Reported by the Patients Using Part I "Symptoms" of SGRO-C
Hide Description Part I of the SGRQ-C covers "symptoms" and is concerned with respiratory symptoms, their frequency and severity. Each questionnaire response has a unique empirically derived "weight". A score was calculated from these weights. The lowest possible value is zero and the highest 100. A higher value corresponds to greater impairment of health status.
Time Frame Baseline, Week 26
Hide Outcome Measure Data
Hide Analysis Population Description
Full analysis set (FAS): all randomized patients who received at least one dose of randomized study drug. Following the ITT principle, patients were analyzed according to the treatment they were assigned to. The FAS was used for all efficacy variables unless otherwise stated
Arm/Group Title QVA149 Plus Placebo to Tiotropium and Placebo to Formoterol Tiotropium Plus Formoterol and Placebo to QVA149
Hide Arm/Group Description:
QVA149 110/50µg, once daily for inhalation use plus placebo to tiotropium, once daily for inhalation use and placebo to formoterol, twice daily for inhalation use.
Tiotropium 18µg, once daily for inhalation use plus Formoterol 12µg, twice daily for inhalation use and placebo to QVA149, once daily for inhalation use.
Overall Number of Participants Analyzed 476 458
Mean (Standard Deviation)
Unit of Measure: Score on a scale
Baseline (n=473,457) 64.10  (19.884) 64.29  (19.768)
Week 26 (n=476,458) 58.31  (21.764) 60.16  (20.678)
Time Frame [Not Specified]
Adverse Event Reporting Description [Not Specified]
 
Arm/Group Title QVA149 Plus Placebo to Tiotropium and Placebo to Formoterol Tiotropium Plus Formoterol and Placebo to QVA149
Hide Arm/Group Description QVA149 110/50µg, once daily for inhalation use plus placebo to tiotropium, once daily for inhalation use and placebo to formoterol, twice daily for inhalation use. Tiotropium 18µg, once daily for inhalation use plus Formoterol 12µg, twice daily for inhalation use and placebo to QVA149, once daily for inhalation use.
All-Cause Mortality
QVA149 Plus Placebo to Tiotropium and Placebo to Formoterol Tiotropium Plus Formoterol and Placebo to QVA149
Affected / at Risk (%) Affected / at Risk (%)
Total   --/--   --/-- 
Hide Serious Adverse Events
QVA149 Plus Placebo to Tiotropium and Placebo to Formoterol Tiotropium Plus Formoterol and Placebo to QVA149
Affected / at Risk (%) Affected / at Risk (%)
Total   30/476 (6.30%)   24/458 (5.24%) 
Cardiac disorders     
Acute myocardial infarction  1  1/476 (0.21%)  0/458 (0.00%) 
Atrial flutter  1  0/476 (0.00%)  1/458 (0.22%) 
Cardiac arrest  1  0/476 (0.00%)  1/458 (0.22%) 
Cardiac failure  1  1/476 (0.21%)  0/458 (0.00%) 
Cardiac failure chronic  1  1/476 (0.21%)  0/458 (0.00%) 
Congestive cardiomyopathy  1  1/476 (0.21%)  0/458 (0.00%) 
Cor pulmonale  1  1/476 (0.21%)  0/458 (0.00%) 
Myocardial infarction  1  3/476 (0.63%)  1/458 (0.22%) 
Myocarditis  1  1/476 (0.21%)  0/458 (0.00%) 
Stress cardiomyopathy  1  0/476 (0.00%)  1/458 (0.22%) 
Tachycardia  1  1/476 (0.21%)  0/458 (0.00%) 
Eye disorders     
Amblyopia  1  1/476 (0.21%)  0/458 (0.00%) 
Cataract cortical  1  1/476 (0.21%)  0/458 (0.00%) 
Cataract nuclear  1  1/476 (0.21%)  0/458 (0.00%) 
Diplopia  1  0/476 (0.00%)  1/458 (0.22%) 
Visual acuity reduced  1  1/476 (0.21%)  0/458 (0.00%) 
Gastrointestinal disorders     
Inguinal hernia  1  1/476 (0.21%)  1/458 (0.22%) 
Intestinal polyp  1  0/476 (0.00%)  1/458 (0.22%) 
General disorders     
Cardiac death  1  0/476 (0.00%)  1/458 (0.22%) 
Death  1  1/476 (0.21%)  0/458 (0.00%) 
Hepatobiliary disorders     
Cholecystitis  1  0/476 (0.00%)  1/458 (0.22%) 
Immune system disorders     
Anaphylactic reaction  1  0/476 (0.00%)  1/458 (0.22%) 
Drug hypersensitivity  1  1/476 (0.21%)  0/458 (0.00%) 
Infections and infestations     
Gastroenteritis  1  0/476 (0.00%)  1/458 (0.22%) 
Pneumonia  1  0/476 (0.00%)  4/458 (0.87%) 
Injury, poisoning and procedural complications     
Cervical vertebral fracture  1  1/476 (0.21%)  0/458 (0.00%) 
Chest injury  1  1/476 (0.21%)  0/458 (0.00%) 
Contusion  1  1/476 (0.21%)  0/458 (0.00%) 
Humerus fracture  1  0/476 (0.00%)  1/458 (0.22%) 
Joint injury  1  0/476 (0.00%)  1/458 (0.22%) 
Rib fracture  1  2/476 (0.42%)  0/458 (0.00%) 
Road traffic accident  1  1/476 (0.21%)  0/458 (0.00%) 
Spinal fracture  1  0/476 (0.00%)  1/458 (0.22%) 
Musculoskeletal and connective tissue disorders     
Back pain  1  1/476 (0.21%)  0/458 (0.00%) 
Cervical spinal stenosis  1  1/476 (0.21%)  0/458 (0.00%) 
Intervertebral disc protrusion  1  2/476 (0.42%)  0/458 (0.00%) 
Osteochondrosis  1  0/476 (0.00%)  1/458 (0.22%) 
Rhabdomyolysis  1  1/476 (0.21%)  0/458 (0.00%) 
Spinal column stenosis  1  0/476 (0.00%)  1/458 (0.22%) 
Synovitis  1  1/476 (0.21%)  0/458 (0.00%) 
Neoplasms benign, malignant and unspecified (incl cysts and polyps)     
Breast cancer  1  1/476 (0.21%)  0/458 (0.00%) 
Lung neoplasm malignant  1  1/476 (0.21%)  0/458 (0.00%) 
Oesophageal carcinoma  1  1/476 (0.21%)  0/458 (0.00%) 
Oropharyngeal cancer stage unspecified  1  1/476 (0.21%)  0/458 (0.00%) 
Nervous system disorders     
Brain injury  1  0/476 (0.00%)  1/458 (0.22%) 
Cerebral ischaemia  1  1/476 (0.21%)  0/458 (0.00%) 
Cerebrovascular accident  1  1/476 (0.21%)  0/458 (0.00%) 
Myoclonus  1  0/476 (0.00%)  1/458 (0.22%) 
Nystagmus  1  0/476 (0.00%)  1/458 (0.22%) 
Psychiatric disorders     
Depression  1  0/476 (0.00%)  1/458 (0.22%) 
Renal and urinary disorders     
Haematuria  1  0/476 (0.00%)  1/458 (0.22%) 
Renal failure  1  1/476 (0.21%)  0/458 (0.00%) 
Respiratory, thoracic and mediastinal disorders     
Dyspnoea  1  0/476 (0.00%)  3/458 (0.66%) 
Haemothorax  1  1/476 (0.21%)  0/458 (0.00%) 
Pneumothorax  1  0/476 (0.00%)  1/458 (0.22%) 
Pulmonary embolism  1  2/476 (0.42%)  1/458 (0.22%) 
Respiratory failure  1  1/476 (0.21%)  0/458 (0.00%) 
Surgical and medical procedures     
Inguinal hernia repair  1  0/476 (0.00%)  1/458 (0.22%) 
Laryngeal fistula repair  1  0/476 (0.00%)  1/458 (0.22%) 
Mastectomy  1  1/476 (0.21%)  0/458 (0.00%) 
Umbilical hernia repair  1  0/476 (0.00%)  1/458 (0.22%) 
Vascular disorders     
Peripheral arterial occlusive disease  1  0/476 (0.00%)  1/458 (0.22%) 
Indicates events were collected by systematic assessment
1
Term from vocabulary, 16.0
Hide Other (Not Including Serious) Adverse Events
Frequency Threshold for Reporting Other Adverse Events 3%
QVA149 Plus Placebo to Tiotropium and Placebo to Formoterol Tiotropium Plus Formoterol and Placebo to QVA149
Affected / at Risk (%) Affected / at Risk (%)
Total   72/476 (15.13%)   79/458 (17.25%) 
Infections and infestations     
Nasopharyngitis  1  42/476 (8.82%)  53/458 (11.57%) 
Respiratory, thoracic and mediastinal disorders     
Cough  1  26/476 (5.46%)  20/458 (4.37%) 
Dyspnoea  1  9/476 (1.89%)  15/458 (3.28%) 
Indicates events were collected by systematic assessment
1
Term from vocabulary, 16.0
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety
Results Point of Contact
Layout table for Results Point of Contact information
Name/Title: Study Director
Organization: Novartis Pharnaceuticals
Phone: 862-778-8300
EMail: trialandresults.registries@novartis.com
Layout table for additonal information
Responsible Party: Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier: NCT01574651    
Other Study ID Numbers: CQVA149ADE01
2011-004870-26 ( EudraCT Number )
First Submitted: April 6, 2012
First Posted: April 10, 2012
Results First Submitted: March 27, 2014
Results First Posted: April 29, 2014
Last Update Posted: May 22, 2014